Download the brochure Health & Wellbeing
Get it
C5KH

Health & Wellbeing

UCITS ETF
Holdings 74
Expense ratio 0.49%
Ticker C5KH
ISIN IE0001EY64U4

Fund Vision

The CIRCA5000 Health & Wellbeing UCITS ETF (C5KH) aims to ensure the world’s population has access to the health-related goods and services needed to live a healthful life. Access to healthcare services across and within countries varies significantly. Life expectancy globally is far from equal — there is a 30-year gap between Japan (85 years) and Lesotho (55 years). At least half of the world’s population does not have access to essential health services without being forced into financial poverty (WHO). The investee companies within C5KH aim to improve health impacts for people worldwide. C5KH aims to deliver investment results corresponding to the Bita CIRCA5000 Health & Wellbeing Impact Index.

As at 30/05/2024

Sub-theme Breakdown

Check out the specific areas of growth and innovation that this fund targets.

  1. Pharma & Biotech 51.5%
  2. Healthcare Products & Services 37.1%
  3. Care & Housing 10.2%

Positive Impact

We use external specialists to provide investment-grade data on the social and environmental outcomes of the companies within our funds.

  • 1.6B Patients Treated
  • 1.1M Lives Extended
  • 359M Sick Days Avoided

CIRCA5000's strategy is to invest in companies that manufacture products, or offer the services that generate a positive environmental or social impact. For example, the homeowner who buys solar panels for their home is ultimately responsible for the positive impact generated and the company that manufactured them is the facilitator. Therefore, by investing in these companies, CIRCA5000 supports users to generate a positive impact, but we are of course, not responsible for it on our own.

This impact is therefore 'associated' rather than direct. We source our data from Net Purpose to ensure we have the most robust and complete data possible.

Data is annual and based on the latest company reports, with some additional products and services estimates provided by Net Purpose.

As at 29/05/2024

Index Performance

Past performance is not a reliable indicator of future performance. The figures in the chart above refer to simulated past performance from the Bita CIRCA5000 Health & Wellbeing Impact Index (BCHWII) established by BITA (www.bitadata.com). It is calculated using backtested performance data from the underlying holdings of the CIRCA5000 Health & Wellbeing UCITS ETF (C5KH) and the data is backtested from 07/03/2014. The performance is backtested index data which has been sourced from the index provider BITA and is based on what they perceive to be reasonable assumptions and objective data. The index currency is based in USD and gross of fees. Factors such as fund fees, trading fees and currency exchange rates may affect your return. The annual TER for C5KH is 0.49%. The index was changed on 07/05/2024 due to a change in impact data provider.

As at 30/05/2024

Fund Holdings

Download spreadsheet
Name
ISIN
AstraZeneca
GB0009895292
5.1%
Novo Nordisk
DK0062498333
4.8%
Danaher
US2358511028
3.8%
CSL
AU000000CSL8
3.6%
Boston Scientific
US1011371077
3.5%
Regeneron Pharmaceuticals
US75886F1075
3.2%
Moderna Inc
US60770K1079
2.8%
Daiichi Sankyo
JP3475350009
2.2%
Tenet Healthcare Corp
US88033G4073
1.7%
Encompass Health Corp
US29261A1007
1.6%
Olympus
JP3201200007
1.5%
Ucb
BE0003739530
1.4%
Pennant Group Inc
US70805E1091
1.4%
Terumo
JP3546800008
1.3%
Addus Homecare Corp
US0067391062
1.3%
Sonova Holding AG
CH0012549785
1.3%
Cooper Companies
US2166485019
1.3%
Ipsen
FR0010259150
1.3%
Corcept Therapeutics
US2183521028
1.3%
Integer Holdings
US45826H1095
1.3%
CryoLife Inc
US2289031005
1.3%
United Therapeutics Corp
US91307C1027
1.3%
Molina Healthcare, Inc.
US60855R1005
1.2%
Cochlear Ltd
AU000000COH5
1.2%
PharmaMar
ES0169501022
1.2%
Globus Medical
US3795772082
1.2%
Insulet Corporation
US45784P1012
1.2%
Bavarian Nordic A/S
DK0015998017
1.2%
Elekta AB (publ)
SE0000163628
1.2%
Neurocrine Biosciences
US64125C1099
1.2%
Chugai Pharmaceuticals
JP3519400000
1.2%
Eisai Co
JP3160400002
1.2%
Ambea
SE0009663826
1.2%
Convatec
GB00BD3VFW73
1.1%
Dr. Reddy's Laboratories Ltd
US2561352038
1.1%
MorphoSys AG
US6177602025
1.1%
Alk-Abello
DK0061802139
1.1%
Amedisys Inc
US0234361089
1.1%
Nihon Kohden Corp
JP3706800004
1.1%
Blueprint Medicines
US09627Y1091
1.1%
National Healthcare
US6359061008
1.1%
Beigene Ltd
US07725L1026
1.1%
Hikma Pharmaceuticals
GB00B0LCW083
1.1%
Sarepta Therapeutics Inc
US8036071004
1.1%
Chemed Corp
US16359R1032
1.1%
Option Care Health Inc
US68404L2016
1.1%
AMN Healthcare Services Inc
US0017441017
1.1%
Camurus
SE0007692850
1.0%
Axonics Inc
US05465P1012
1.0%
Teleflex
US8793691069
1.0%
Sugi Holdings Co Ltd
JP3397060009
1.0%
Agilon Health
US00857U1079
1.0%
Omron
JP3197800000
1.0%
Innoviva
US45781M1018
1.0%
ANI Pharmaceuticals Inc
US00182C1036
1.0%
BioArctic AB
SE0010323311
0.9%
Sonic Healthcare Ltd
AU000000SHL7
0.9%
Towa Pharmaceutical Co Ltd
JP3623150004
0.9%
Demant
DK0060738599
0.9%
Kissei Phramaceuticals
JP3240600001
0.9%
Penumbra Inc
US70975L1070
0.9%
Axsome Therapeutics Inc
US05464T1043
0.9%
Oxford Nanopore Technologies PLC
GB00BP6S8Z30
0.9%
Raffles Medical Group Ltd
SG1CH4000003
0.8%
Liquidia
US53635D2027
0.8%
Teladoc Health Inc
US87918A1051
0.8%
Mirum Phramaceuticals
US6047491013
0.8%
Sunwels
JP3324410004
0.8%
Alkermes
IE00B56GVS15
0.8%
Microport Scientific Corp
KYG608371046
0.8%
Menicon Co Ltd
JP3921270009
0.7%
Attendo
SE0007666110
0.7%
ACADIA Pharmaceuticals Inc
US0042251084
0.7%
Scholar Rock Holding Corp
US80706P1030
0.6%

As at 30/05/2024

Exposure Breakdown

Geography
USA
49.5%
37 Holdings
Japan
13.8%
12 Holdings
UK
8.2%
4 Holdings
Denmark
8.0%
4 Holdings
Australia
5.7%
3 Holdings
Sweden
5.0%
5 Holdings
Belgium
1.4%
1 Holding
Switzerland
1.3%
1 Holding

As at 29/05/2024

Fund Details

Fund AUM
USD 5,111,500
NAV per share
USD 5.11
Number of holdings
74
Ticker (USD)
C5KH
Ticker (GBP)
CKHG
ISIN
IE0001EY64U4
Base Currency
USD
Income Treatment
Accumulating
Inception Date
05/06/2023
Primary Exchange
London Stock Exchange
Total Expense Ratio (TER)
0.49%
Domicile
Ireland
Replication Method
Physical - Full Replication
Index Ticker
BCHWII
Index Provider
BITA GmbH
Issuer
CIRCA5000 ICAV
Promoter
CIRCA5000 UK Ltd
Investment Manager
Vident Advisory, LLC
Custodian
J.P. Morgan SE, Dublin Branch
SFDR Classification
Article 9
UCITS Compliant
Yes
UK Reporting Status
Yes
ISA Eligible
Yes
SIPP Eligible
Yes

Risks

Equity Risk

The fund may invest in equity securities which are subject to greater fluctuations than other assets. Factors which may affect the fluctuation including economic conditions, industry or company news. High volumes of trading may also see increased transaction costs.

Thematic Risk

The Fund may be subject to the risks associated with, but not limited to, investing in companies with a material exposure to the climate transition. These risks include the obsolescence of intellectual property as technology evolves and changes in regulation or government subsidies that may affect the revenue or profitability of a company.

Operational Risk

The Fund and its assets may experience material losses as a result of technology/system failures, human error, policy breaches, and/or incorrect valuation of units.

Market Risk

The risk that the market will go down in value, with the possibility that such changes will be sharp and unpredictable.

Currency Risk

Some of the Fund’s investments may be denominated in currencies other than the Fund’s base currency (USD) therefore investors may be affected by adverse movements of the denominated currency and the base currency.

Sustainability Risk

The Manager, acting in respect of the Fund, through the Investment Manager as its delegate, integrates sustainability risks into the investment decisions made in respect of the Fund. Given the investment strategy of the Fund and its risk profile, the likely impact of sustainability risks on the Fund’s returns is expected to be low.

Derivative Risk

The Fund may invest in Financial Derivative Instruments (FDIs) to hedge against risk, to increase return and/or for efficient portfolio management. There is no guarantee that the Fund’s use of derivatives for any purpose will be successful. Derivatives are subject to counterparty risk (including potential loss of instruments) and are highly sensitive to underlying price movements, interest rates and market volatility and therefore come with a greater risk.

Documents

Explore our other funds